Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | F7 | P08709 | 3/20 | 0.33 |
| ▸ | F3 | P13726 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553058 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL103394 | 0.97 | — | — | |
| SCHEMBL2872079 | 0.97 | — | — | |
| SCHEMBL157060 | 0.97 | — | — | |
| SCHEMBL9652389 | 0.92 | ALDH1A1 (0.46) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL4213848 | 0.92 | ALDH1A1 (0.46) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL9652392 | 0.92 | ALDH1A1 (0.46) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL606595 | 0.88 | ALDH1A1 (0.48) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL5457684 | 0.88 | ALDH1A1 (0.48) | ALDH1A1CYP19A1PPARGOXER1MAPT | |
| SCHEMBL9766336 | 0.88 | ALDH1A1 (0.48) | ALDH1A1CYP19A1PPARGOXER1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031130-B2 | Composition for modifying target gene | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11993570-B2 | Cationic lipids | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| EP-3733641-B1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-111511713-B | Cationic lipid | 武田药品工业株式会社 | 2024-01-02 | — | — | CN | disclosed |
| CN-111527204-B | Composition for target gene modification | 国立大学法人京都大学 | 2023-09-01 | — | — | CN | disclosed |
| US-20230257338-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3733844-A1 | COMPOSITION FOR MODIFYING TARGET GENE | Kyoto University (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733641-A1 | CATIONIC LIPIDS | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20200331841-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993570-B2 | Cationic lipids | ELOVL5, LPCAT3, ELOVL3 | ALDH1A1 3506/4885CYP19A1 3557/4885PPARG 2275/4885 |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | NSUN2, NSUN3, RNASE1 | ALDH1A1 3452/4885CYP19A1 3710/4885PPARG 3442/4885 |
| US-12031130-B2 | Composition for modifying target gene | NSUN2, NSUN3, RNASE1 | ALDH1A1 3452/4885CYP19A1 3710/4885PPARG 3442/4885 |
| US-20230257338-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | ALDH1A1 3506/4885CYP19A1 3557/4885PPARG 2275/4885 |
| US-20200331841-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | ALDH1A1 3506/4885CYP19A1 3557/4885PPARG 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.